Multidrug Resistance In The Standardized Treatment of Colon Cancer Harboring A Rare Fibrosarcoma B-Type (BRAF) PN581I Mutation: A Case Report

Authors

Xiaoyan Wang
Chenyi Zhao
Yang Gong
Ying Wang
Feng Guo

Publication Date

1-1-2023

Journal

Frontiers in Oncology

Abstract

BRAF non-V600 mutations are a distinct molecular subset of colorectal cancer (CRC) that has little to no clinical similarity to the BRAF V600 mutations. It is generally considered that the BRAF non-V600 mutations correlate with better survival of CRC patients. In this report, we present an unusual case of that a midlife female patient who was initially diagnosed with stage IIIC colon cancer, and multiple metastases were found 25 months after radical surgery. Next-generation sequencing (NGS) revealed the BRAF p.N581I (c.1742A>T) mutation. She received chemotherapy, targeted therapy, and immunotherapy. However, the disease progressed rapidly with rare metastasis of the bone and cerebellum. This case highlights that the BRAF non-V600 mutations, such as BRAF p.N581I mutant, may lead to resistance to epidermal growth factor receptor (EGFR) inhibitors and result in a rapid course in colorectal cancer. The role of BRAF p.N581I mutation in colorectal cancer demands more attention.

Keywords

BRAF p.N581I, colorectal cancer metastasis, targeted therapy, immunotherapy, multidrug resistance, anti-EGFR monoclonal antibody

Comments

Supplementary Materials

DOI

10.3389/fonc.2023.1175693

PMID

37519790

PMCID

PMC10380923

PubMedCentral® Posted Date

July 2023

PubMedCentral® Full Text Version

Post-Print